Research programme: human monoclonal antibodies - Sanofi/Kirin Brewery
Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation; Kirin Brewery
- Developer Kirin Holdings Company; Sanofi
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Oct 2008 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 24 Oct 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 May 2006 This programme is still in active development